Insmed iPlex Growth Agent "Approvable" Letter Skirts Orphan Status Issue
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s "approvable" letter for Insmed’s mecasermin rinfibate growth treatment requests clarification of chemistry, manufacturing and controls data but does not address the product’s orphan drug status.